An inhibitor of JAK1 exhibits "remarkable" activity in T-cell lymphoma.

Published Date: 18 Dec 2023

An accelerated approval application for golidocitinib will be based on phase II results.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

2.

An inhibitor of JAK1 exhibits "remarkable" activity in T-cell lymphoma.

3.

Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies

4.

Breast cancer surgery: Study finds overnight hospital stay not important for older patients

5.

As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot